Lv3
394 积分 2021-08-24 加入
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)
2天前
已完结
Abstract CT029: Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial
3天前
已关闭
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
3天前
已完结
Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial
3天前
求助中
Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer
4天前
已完结
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
4天前
已完结
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
5天前
已完结
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours
5天前
已完结
Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial
9天前
已关闭
Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial
9天前
已关闭
皖公网安备34019202002308
